Literature DB >> 35609160

High-Dose Pulse Steroids for the Treatment of Acute Hypoxemic Respiratory Failure in COVID-19 Pneumonia: A Simple Case Series.

Gholmieh Ghassan1.   

Abstract

Pulse steroids therapy is widely used to treat flare-ups of autoimmune diseases, such as systemic lupus erythematosus. The main assumption is that severe inflammation caused by an autoimmune disease must be aggressively quelled before it causes further damage. We present a series of 9 cases that explore the use of high-dose pulse steroids in hypoxemic respiratory failure. We used high-dose steroids to alter the outcome of some patients, using commonly accepted protocols such as 6 mg of dexamethasone via IV, baricitinib, and tocilizumab. The outcome of each case is discussed. The patients were treated with 500 mg of high-dose methylprednisolone via IV for 3 days, followed by 250 mg via IV for 3 days; followed by 12 or 6 mg of dexamethasone was administered daily by mouth or IV. A retrospective review of patients who received a computerized tomography pulmonary angiogram showed that these patients had organizing pneumonia features. Eight out of nine cases had a favorable outcome.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35609160      PMCID: PMC9126540          DOI: 10.7812/TPP/21.090

Source DB:  PubMed          Journal:  Perm J        ISSN: 1552-5767


  18 in total

1.  [Steroid pulse -therapy in patients With coronAvirus Pneumonia (COVID-19), sYstemic inFlammation And Risk of vEnous thRombosis and thromboembolism (WAYFARER Study)].

Authors:  V Yu Mareev; Ya A Orlova; E P Pavlikova; S T Matskeplishvili; T N Krasnova; P S Malahov; L M Samokhodskaya; E A Mershina; V E Sinitsyn; Yu V Mareev; A L Kalinkin; Yu L Begrambekova; A A Kamalov
Journal:  Kardiologiia       Date:  2020-07-07       Impact factor: 0.395

2.  Comparison of Associations Between Glucocorticoids Treatment and Mortality in COVID-19 Patients and SARS Patients: A Systematic Review and Meta-Analysis.

Authors:  Jianbo Li; Xuelian Liao; Yue Zhou; Luping Wang; Hang Yang; Wei Zhang; Zhongwei Zhang; Yan Kang
Journal:  Shock       Date:  2021-08-01       Impact factor: 3.454

3.  Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.

Authors:  Bruno M Tomazini; Israel S Maia; Alexandre B Cavalcanti; Otavio Berwanger; Regis G Rosa; Viviane C Veiga; Alvaro Avezum; Renato D Lopes; Flavia R Bueno; Maria Vitoria A O Silva; Franca P Baldassare; Eduardo L V Costa; Ricardo A B Moura; Michele O Honorato; Andre N Costa; Lucas P Damiani; Thiago Lisboa; Letícia Kawano-Dourado; Fernando G Zampieri; Guilherme B Olivato; Cassia Righy; Cristina P Amendola; Roberta M L Roepke; Daniela H M Freitas; Daniel N Forte; Flávio G R Freitas; Caio C F Fernandes; Livia M G Melro; Gedealvares F S Junior; Douglas Costa Morais; Stevin Zung; Flávia R Machado; Luciano C P Azevedo
Journal:  JAMA       Date:  2020-10-06       Impact factor: 56.272

4.  Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial.

Authors:  Maryam Edalatifard; Maryam Akhtari; Mohammadreza Salehi; Zohre Naderi; Ahmadreza Jamshidi; Shayan Mostafaei; Seyed Reza Najafizadeh; Elham Farhadi; Nooshin Jalili; Masoud Esfahani; Besharat Rahimi; Hossein Kazemzadeh; Maedeh Mahmoodi Aliabadi; Tooba Ghazanfari; Mohammadreza Sattarian; Hourvash Ebrahimi Louyeh; Seyed Reza Raeeskarami; Saeidreza Jamalimoghadamsiahkali; Nasim Khajavirad; Mahdi Mahmoudi; Abdolrahman Rostamian
Journal:  Eur Respir J       Date:  2020-12-24       Impact factor: 16.671

5.  Dexamethasone in Hospitalized Patients with Covid-19.

Authors:  Peter Horby; Wei Shen Lim; Jonathan R Emberson; Marion Mafham; Jennifer L Bell; Louise Linsell; Natalie Staplin; Christopher Brightling; Andrew Ustianowski; Einas Elmahi; Benjamin Prudon; Christopher Green; Timothy Felton; David Chadwick; Kanchan Rege; Christopher Fegan; Lucy C Chappell; Saul N Faust; Thomas Jaki; Katie Jeffery; Alan Montgomery; Kathryn Rowan; Edmund Juszczak; J Kenneth Baillie; Richard Haynes; Martin J Landray
Journal:  N Engl J Med       Date:  2020-07-17       Impact factor: 91.245

6.  Severe organising pneumonia following COVID-19.

Authors:  István Vadász; Faeq Husain-Syed; Peter Dorfmüller; Fritz C Roller; Khodr Tello; Matthias Hecker; Rory E Morty; Stefan Gattenlöhner; Hans-Dieter Walmrath; Friedrich Grimminger; Susanne Herold; Werner Seeger
Journal:  Thorax       Date:  2020-11-11       Impact factor: 9.139

7.  Organizing pneumonia of COVID-19: Time-dependent evolution and outcome in CT findings.

Authors:  Yan Wang; Chao Jin; Carol C Wu; Huifang Zhao; Ting Liang; Zhe Liu; Zhijie Jian; Runqing Li; Zekun Wang; Fen Li; Jie Zhou; Shubo Cai; Yang Liu; Hao Li; Yukun Liang; Cong Tian; Jian Yang
Journal:  PLoS One       Date:  2020-11-11       Impact factor: 3.240

8.  Second week methyl-prednisolone pulses improve prognosis in patients with severe coronavirus disease 2019 pneumonia: An observational comparative study using routine care data.

Authors:  Guillermo Ruiz-Irastorza; Jose-Ignacio Pijoan; Elena Bereciartua; Susanna Dunder; Jokin Dominguez; Paula Garcia-Escudero; Alejandro Rodrigo; Carlota Gomez-Carballo; Jimena Varona; Laura Guio; Marta Ibarrola; Amaia Ugarte; Agustin Martinez-Berriotxoa
Journal:  PLoS One       Date:  2020-09-22       Impact factor: 3.240

Review 9.  SARS-CoV-2 organising pneumonia: 'Has there been a widespread failure to identify and treat this prevalent condition in COVID-19?'

Authors:  Pierre Kory; Jeffrey P Kanne
Journal:  BMJ Open Respir Res       Date:  2020-09

10.  Can steroids reverse the severe COVID-19 induced "cytokine storm"?

Authors:  Lykourgos Kolilekas; Konstantinos Loverdos; Styliani Giannakaki; Lamprini Vlassi; Anastasia Levounets; Eleftherios Zervas; Mina Gaga
Journal:  J Med Virol       Date:  2020-06-29       Impact factor: 20.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.